Plant Name: Descurainia sophia
Taxonomic Information:
Plant ID: NPO12405
Plant Latin Name: Descurainia sophia
Taxonomy Genus: Descurainia
Taxonomy Family: Brassicaceae
Plant External Links:
NCBI TaxonomyDB:
89411
Plant-of-the-World-Online:
78248-2
Used in Medicines:
Country/Region:
China; India; TurkmenistanTraditional Medicine System:
Indian Folk; TCMGeographical Distribution:
Turkey; Italy; Turkmenistan; Nepal; Mongolia; France; Ireland; Argentina; Norway; Uzbekistan; Belarus; Iran; Algeria; Iceland; China; Chile; Belgium; Germany; Iraq; Kazakhstan; Spain; Ukraine; Netherlands; Denmark; Poland; Finland; United States; Morocco; Sweden; Greenland; Japan; Switzerland; New Zealand; Russia; Bulgaria; Pakistan; Romania; Albania; Portugal; Mexico; Egypt; South Africa; India; United Kingdom; Austria; Greece; Hungary; Tajikistan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| NPSR1; | |
| MIF; ALOX12; HSD17B10; ALOX15; NOX4; POLB; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA7; CA4; | |
| LMNA; FABP3; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.484E-09 | 1.625E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.475E-07 | 1.338E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 1.982E-07 | 1.660E-04 | ALOX12, CA12, CA2, CA7, FABP3, FABP4, FFAR1, MET, NOX4, NPSR1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.375E-07 | 2.534E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.742E-06 | 8.822E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.742E-06 | 8.822E-04 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 2.035E-06 | 9.845E-04 | ALOX15, AXL, CYP1A1, CYP1B1, FABP4, FFAR4, FLT3, IGF1R, KDR, NOX4 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 4.379E-06 | 1.703E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.222E-06 | 1.880E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 5.222E-06 | 1.880E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 5.222E-06 | 1.880E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 5.654E-06 | 1.986E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 5.796E-06 | 2.003E-03 | ALOX15, FFAR4, KDR, MIF, NOX4 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 6.198E-06 | 2.054E-03 | FABP3, FABP4, FFAR4 |
| BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 1.002E-05 | 3.073E-03 | ALOX12, CYP1A1, CYP1B1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.738E-05 | 4.505E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0036094; small molecule binding | 2.746E-05 | 6.644E-03 | AURKB, AXL, CDK1, FABP3, FABP4, FFAR4, FLT3, IGF1R, KDR, MET, NOX4, PIM1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.959E-05 | 7.003E-03 | CYP1A1, CYP1B1, NOX4 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 3.644E-05 | 8.264E-03 | FLT3, KDR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.278E-09 | 3.695E-07 | CA12, CA2, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.671E-05 | 1.285E-03 | CYP1A1, CYP1B1, IGF1R |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 4.043E-04 | 9.434E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
